Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06575959 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT06575959 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 20 participants.
The verdict
NCT06575959, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Researchers have designed a new study medicine called enlicitide decanoate as a new way to lower the amount of low-density lipoprotein cholesterol (LDL-C) in a person's blood. Enlicitide decanoate will be called "enlicitide" from this point forward, The purpose of this study is to learn what happens to enlicitide in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to enlicitide in the body when it is given to people with hepatic impairment (HI- meaning the liver does not work properly) and people who are in good health. This study will have 2 parts. In Part 1, enlicitide will be given to people with moderate HI and people who are in good health. After Part 1, researchers may decide to include people who have mild HI and compare what happens to enlicitide in the body with people who are in good health.
Interventions
- DRUG Enlicitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-20 |
| Est. Completion | 2025-05-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06575959
The ClinicalTrials.gov registry entry for NCT06575959 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enlicitide is the first listed.
NCT06575959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06575959 about?
NCT06575959 is a clinical study titled "A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)". Researchers have designed a new study medicine called enlicitide decanoate as a new way to lower the amount of low-density lipoprotein cholesterol (LDL-C) in a person's blood. Enlicitide decanoate will be called "enlicitide" from this point forward, The purpose of this study is to learn what happen...
What is the current status of trial NCT06575959?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-09-20. Estimated completion is 2025-05-08.
What interventions are being tested in trial NCT06575959?
The interventions under investigation include: Enlicitide (DRUG).
Who is sponsoring clinical trial NCT06575959?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.